AR037239A1 - Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento. - Google Patents
Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento.Info
- Publication number
- AR037239A1 AR037239A1 ARP020103627A ARP020103627A AR037239A1 AR 037239 A1 AR037239 A1 AR 037239A1 AR P020103627 A ARP020103627 A AR P020103627A AR P020103627 A ARP020103627 A AR P020103627A AR 037239 A1 AR037239 A1 AR 037239A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- preparation
- valdecoxib
- medicinal product
- acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical group CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002004 valdecoxib Drugs 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32535601P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037239A1 true AR037239A1 (es) | 2004-11-03 |
Family
ID=23267542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103627A AR037239A1 (es) | 2001-09-26 | 2002-09-26 | Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20030181501A1 (enExample) |
| EP (2) | EP1490035A1 (enExample) |
| JP (2) | JP2005506987A (enExample) |
| KR (2) | KR20040058189A (enExample) |
| CN (2) | CN1633281A (enExample) |
| AP (2) | AP2004002998A0 (enExample) |
| AR (1) | AR037239A1 (enExample) |
| BR (2) | BR0212861A (enExample) |
| CA (2) | CA2461044A1 (enExample) |
| CO (2) | CO5570659A2 (enExample) |
| EA (2) | EA200400357A1 (enExample) |
| EC (1) | ECSP045029A (enExample) |
| GE (1) | GEP20063856B (enExample) |
| HK (1) | HK1079988A1 (enExample) |
| IL (2) | IL160848A0 (enExample) |
| IS (2) | IS7177A (enExample) |
| MA (2) | MA27542A1 (enExample) |
| MX (2) | MXPA04002652A (enExample) |
| NO (2) | NO20041258L (enExample) |
| OA (2) | OA13060A (enExample) |
| PL (2) | PL369298A1 (enExample) |
| TN (2) | TNSN04045A1 (enExample) |
| WO (2) | WO2003026623A1 (enExample) |
| YU (1) | YU34804A (enExample) |
| ZA (2) | ZA200401953B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050186271A1 (en) * | 2004-02-24 | 2005-08-25 | Sheskey Paul J. | Process for dispersing a fluid in a mass of solid particles |
| JP5551852B2 (ja) * | 2004-08-10 | 2014-07-16 | 味の素株式会社 | 苦味の低減したナテグリニド含有製剤 |
| JP5209876B2 (ja) * | 2004-12-28 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 速崩壊性錠剤及びその製造方法 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| CN101340899A (zh) * | 2005-12-20 | 2009-01-07 | 卫材R&D管理有限公司 | 含有脂溶性药物的口腔内速崩片 |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
| US20070196494A1 (en) * | 2006-02-17 | 2007-08-23 | Arnaud Grenier | Low-friability, patient-friendly orally disintegrating formulations |
| JP2009537554A (ja) * | 2006-05-19 | 2009-10-29 | ソマクソン ファーマシューティカルズ インコーポレイテッド | 不眠症を治療するための、口腔内、舌下および急速融解製剤を含む、低用量ドキセピン製剤、ならびにその使用 |
| KR101903781B1 (ko) * | 2007-06-06 | 2018-11-13 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| JP2010529071A (ja) * | 2007-06-06 | 2010-08-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 速崩性錠剤製造のための医薬製剤 |
| KR20100033400A (ko) * | 2007-06-06 | 2010-03-29 | 바스프 에스이 | 급속 붕해 정제의 제조를 위한 제약 제제 |
| WO2008148734A1 (de) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmazeutische formulierung für die herstellung von kau- und lutsch-tabletten |
| CA2704929C (en) * | 2007-08-07 | 2018-05-15 | Pamela Palmer | Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms |
| WO2009118589A2 (en) | 2008-03-24 | 2009-10-01 | Wockhardt Research Centre | Orally disintegrating compositions of rhein or diacerein |
| US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| CN102988318A (zh) * | 2008-11-25 | 2013-03-27 | 田边三菱制药株式会社 | 口腔速崩片及其制备方法 |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
| FR2968995B1 (fr) * | 2010-12-16 | 2013-03-22 | Sanofi Aventis | Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage |
| CN106822007B (zh) | 2015-09-11 | 2021-12-31 | 西姆莱斯股份公司 | 口服制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| SK74396A3 (en) * | 1995-06-13 | 1997-04-09 | American Home Prod | Organoleptically acceptable oral pharmaceutical compositions |
| DK0855988T3 (da) * | 1995-10-20 | 2002-08-19 | Upjohn Co | Blisterpakning |
| SK284330B6 (sk) * | 1996-05-17 | 2005-01-03 | Merck & Co., Inc. | Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu |
| EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
| US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
| CA2362816C (en) * | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Valdecoxib compositions |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| EP1309315B1 (en) * | 2000-08-18 | 2006-06-14 | Pharmacia Corporation | Rapidly disintegrating oral formulation of valdecoxib |
-
2002
- 2002-09-23 PL PL02369298A patent/PL369298A1/xx not_active Application Discontinuation
- 2002-09-23 EA EA200400357A patent/EA200400357A1/ru unknown
- 2002-09-23 WO PCT/US2002/030161 patent/WO2003026623A1/en not_active Ceased
- 2002-09-23 BR BR0212861-6A patent/BR0212861A/pt not_active IP Right Cessation
- 2002-09-23 HK HK06100055.6A patent/HK1079988A1/zh unknown
- 2002-09-23 US US10/252,222 patent/US20030181501A1/en not_active Abandoned
- 2002-09-23 AP APAP/P/2004/002998A patent/AP2004002998A0/en unknown
- 2002-09-23 EP EP02775948A patent/EP1490035A1/en not_active Withdrawn
- 2002-09-23 WO PCT/US2002/030048 patent/WO2003026697A2/en not_active Ceased
- 2002-09-23 IL IL16084802A patent/IL160848A0/xx unknown
- 2002-09-23 EP EP02773522A patent/EP1429736A2/en not_active Withdrawn
- 2002-09-23 EA EA200400352A patent/EA200400352A1/ru unknown
- 2002-09-23 BR BR0212778-4A patent/BR0212778A/pt not_active IP Right Cessation
- 2002-09-23 AP APAP/P/2004/002999A patent/AP2004002999A0/en unknown
- 2002-09-23 YU YU34804A patent/YU34804A/sh unknown
- 2002-09-23 IL IL16085502A patent/IL160855A0/xx unknown
- 2002-09-23 PL PL02369297A patent/PL369297A1/xx not_active Application Discontinuation
- 2002-09-23 CA CA002461044A patent/CA2461044A1/en not_active Abandoned
- 2002-09-23 JP JP2003530331A patent/JP2005506987A/ja not_active Withdrawn
- 2002-09-23 MX MXPA04002652A patent/MXPA04002652A/es unknown
- 2002-09-23 KR KR10-2004-7004334A patent/KR20040058189A/ko not_active Ceased
- 2002-09-23 OA OA1200400082A patent/OA13060A/en unknown
- 2002-09-23 OA OA1200400083A patent/OA12707A/en unknown
- 2002-09-23 CN CNA028211413A patent/CN1633281A/zh active Pending
- 2002-09-23 JP JP2003530260A patent/JP2005512964A/ja not_active Withdrawn
- 2002-09-23 CN CNA028189078A patent/CN1703203A/zh active Pending
- 2002-09-23 KR KR10-2004-7004373A patent/KR20040044990A/ko not_active Ceased
- 2002-09-23 CA CA002461630A patent/CA2461630A1/en not_active Abandoned
- 2002-09-23 MX MXPA04002798A patent/MXPA04002798A/es unknown
- 2002-09-23 GE GE5525A patent/GEP20063856B/en unknown
- 2002-09-26 AR ARP020103627A patent/AR037239A1/es unknown
-
2004
- 2004-03-10 ZA ZA200401953A patent/ZA200401953B/en unknown
- 2004-03-11 IS IS7177A patent/IS7177A/is unknown
- 2004-03-11 IS IS7178A patent/IS7178A/is unknown
- 2004-03-23 TN TNP2004000045A patent/TNSN04045A1/fr unknown
- 2004-03-23 EC EC2004005029A patent/ECSP045029A/es unknown
- 2004-03-24 MA MA27587A patent/MA27542A1/fr unknown
- 2004-03-24 MA MA27586A patent/MA27682A1/fr unknown
- 2004-03-24 TN TNP2004000047A patent/TNSN04047A1/fr unknown
- 2004-03-25 NO NO20041258A patent/NO20041258L/no not_active Application Discontinuation
- 2004-03-25 ZA ZA200402364A patent/ZA200402364B/xx unknown
- 2004-03-26 CO CO04028410A patent/CO5570659A2/es not_active Application Discontinuation
- 2004-03-26 CO CO04028409A patent/CO5570684A2/es not_active Application Discontinuation
- 2004-04-15 NO NO20041532A patent/NO20041532L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9916224A (pt) | Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola | |
| IL116084A0 (en) | Pharmaceutical compositions containing ondansetron and their use | |
| CU20000176A7 (es) | Composiciones de celecoxib | |
| CY1113375T1 (el) | Εκχυλιση φαρμακευτικα δραστικων κανναβινοειδων απο φυτικα υλικα | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| ATE215816T1 (de) | Feste oral anzuwendende arzeneiform | |
| HUP0302131A2 (hu) | Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| LV12632A (lv) | Pyrazoline derivatives their preparation and application as medicaments | |
| BR0212778A (pt) | Composições de desintegração intra-oral organolepticamente aceitáveis | |
| HUT77092A (hu) | Egy kompetitív progeszteron-antagonistát és egy gesztagént tartalmazó kombinációs készítmény alkalmazása endometriosis vagy leiomiomata uteri kezelésére szolgáló gyógyszerkészítmények előállítására | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| PE20250018A1 (es) | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| EP4480545A3 (en) | Formulations of a plasma kallikrein inhibitor | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| HUP0004461A2 (hu) | Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| JP2015078166A (ja) | 口腔内速崩壊性錠剤用組成物 | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| MX2025000908A (es) | Composiciones farmaceuticas de nor-udca | |
| MXPA04004290A (es) | Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |